李 聪,张 悦,任延律.整合素β3在三阴性乳腺癌中的表达及其与预后的关系[J].肿瘤学杂志,2016,22(12):1037-1041. |
整合素β3在三阴性乳腺癌中的表达及其与预后的关系 |
Expression of Integrin β3 in Triple Negative Breast Cancer and Its Prognostic Significance |
投稿时间:2016-05-08 |
DOI:10.11735/j.issn.1671-170X.2016.12.B011 |
|
|
中文关键词: 三阴性乳腺癌 整合素β3 预后 |
英文关键词:integrin β3 triple negative breast cancer prognosis |
基金项目:黑龙江省自然科学基金项目(H2015051) |
|
摘要点击次数: 2186 |
全文下载次数: 660 |
中文摘要: |
摘 要:[目的] 探讨整合素β3在三阴性乳腺癌中的临床意义。[方法] 免疫组织化学染色法检测98例三阴性乳腺癌组织中整合素β3的表达情况。[结果] 在三阴性乳腺癌患者中整合素β3表达与患者的绝经状态及淋巴结转移状态密切相关(P<0.05)。整合素β3阳性的三阴性乳腺癌患者的5年无病生存时间及乳腺癌特异性生存时间均显著差于整合素β3阴性者。Cox多因素分析显示整合素β3是三阴性乳腺癌预后不良的独立危险因素(HR=1.910,95%CI:1.069~3.413;P=0.029)。[结论] 整合素β3可作为判断三阴性乳腺癌预后的重要指标及潜在的治疗靶点。 |
英文摘要: |
Abstract:[Objective] To explore the clinical significance of integrin β3expression in triple negative breast cancer (TNBC). [Methods] The expression of integrin β3 was detected in 98 patients with TNBC by immunohistochemical staining. [Results] Integrin β3 was significantly associated with menopausal status and lymph node status(P<0.05). Patients with positive integrin β3 expression had worse 5-year disease-free survival and breast cancer-specific survival than patients with negative expression. Cox multivariate analysis showed that integrin β3 was an independent unfavorable prognostic factor for patients with TNBC(HR=1.910,95%CI:1.069~3.413;P=0.029). [Conclusion] Integrin β3 can be used as the prognostic marker and potential therapy target for TNBC. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |